



Lyka Labs Limited

MANUFACTURERS OF PHARMACEUTICALS.

Administrative Office: 101, Shiv Shakti Industrial Estate, Sir. M. V. Road, Andheri (E), Mumbai-400 059
Registered Office: 4801/B & 4802/A, G.I.D.C Industrial Estate, Ankleshwar-393 002.
CIN: L2430GJ1976PLC008738

EXTRACT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2016

(₹ in Lacs)

PARTICULARS	Quarter ended			Year to date figure for the current period ended	Year to date figure for the Previous period ended	Previous Period ended
	30-09-16	30-06-16	30-09-15	30-09-16	30-09-15	31-03-16
Sr. No.	(Unaudited)	(Unaudited)	(Unaudited)	6 Month (Unaudited)	3 Months (Unaudited)	9 Month (Audited)
1 Total Income from operations (Net)	3290.02	2,117.97	3,538.81	5,407.99	3,538.81	13,040.90
2 Net Profit/(Loss) from ordinary activities after Tax	98.36	(415.92)	1,793.96	(317.56)	1,793.96	408.99
3 Net Profit/(Loss) for the period after Tax (after Extra ordinary items)	98.36	(415.92)	1,793.96	(317.56)	1,793.96	408.99
4 Paid Up Equity Share Capital (Face value of ₹10/-share)	2,204.00	2,204.00	2,158.00	2,204.00	2,158.00	2,204.00
5 Reserve excluding Revaluation Reserve as shown in the balance sheet of previous year						1,527.19
6 Earnings per share in ₹ (before Extraordinary items) of ₹10 each						
Basic	0.21	(1.89)	6.26	(1.68)	6.26	1.65
Diluted	0.21	(1.89)	6.26	(1.68)	6.26	1.65
7 Earnings per share in ₹ (after Extraordinary items) of ₹ 10 each						
Basic	0.21	(1.89)	6.26	(1.68)	6.26	1.65
Diluted	0.21	(1.89)	6.26	(1.68)	6.26	1.65

EXTRACT OF CONSOLIDATED UNAUDITED STATEMENT OF ASSETS AND LIABILITIES FOR THE PERIOD ENDED ON 30TH SEPTEMBER 2016

₹ in Lacs

PARTICULARS	As at		PARTICULARS	As at	
	30 th Sep, 2016	31 st March, 2016		30 th Sep, 2016	31 st March, 2016
	Unaudited	Audited		Unaudited	Audited
A EQUITY AND LIABILITIES			B ASSETS		
1 Shareholders' Funds			1 Non-Current Assets		
(a) Share Capital	2,312.57	2,312.57	(a) Fixed Assets		
(b) Reserves and Surplus	1,748.33	2,211.49	(i) Tangible Assets	5,531.43	5,665.91
Sub-Total-Shareholders' Fund	4,060.90	4,524.06	(ii) Capital Work-in-Progress	1,792.10	1,736.28
2 Minority Interest	437.62	391.31	(iii) Intangible Assets	4,594.03	4,756.82
3 Non-Current Liabilities			(iv) Intangible assets under development	1,318.14	1,280.66
(a) Long-Term Borrowings	2,933.13	2,531.45		13,235.70	13,439.67
(b) Other Long-Term Liabilities	200.95	139.95	(b) Non-Current Investments	28.65	38.65
(c) Deferred Tax Liability	-	-	(c) Deferred Tax Asset	125.60	111.24
(d) Long-Term Provisions	305.29	291.70	(d) Long-Term Loans and Advances	2,531.73	2,391.57
Sub-Total-Non-Current liabilities	3,439.37	2,963.10	Sub-Total-Non-Current assets	15,921.68	15,961.13
4 Current Liabilities			2 Current Assets		
(a) Short-Term Borrowings	6,088.75	5,994.81	(a) Inventories	1,254.43	1,081.16
(b) Trade Payables	5,279.64	4,420.95	(b) Trade Receivables	5,023.61	4,329.49
(c) Other Current Liabilities	5,681.20	5,441.94	(c) Cash and Cash Equivalents	526.61	555.52
(d) Short-Term Provisions	433.25	425.79	(d) Short-Term Loans and Advances	2,451.39	1,969.56
Sub-Total-Current liabilities	17,482.84	16,283.49	(e) Other Current Assets	243.01	245.10
TOTAL-EQUITY AND LIABILITIES	25,420.73	24,161.96	Sub-Total-Current assets	9,499.05	8,180.83
			TOTAL-ASSETS	25,420.73	24,161.96

Notes:

The above is an extract of the detailed format of quarterly/Half yearly Financial results filed with the stock Exchange under Regulation 33 of the SEBI (Listing and other disclosure requirements) Regulations, 2015. The full format of quarterly/Half yearly financial results are available on the Stock Exchange Websites. (www.nseindia.com, www.bseindia.com)

- The results have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company along with Limited Review Report carried out by the Auditors at its meeting held on 5th Nov, 2016
- During the quarter the Holding Company has charged ₹ 21.42 lacs to Statement of Profit & Loss, being depreciation on revalued assets.
- During the quarter the Holding Company has capitalised interest of ₹ 20.67 lacs and allocable expenses of ₹ 8.43 lacs towards Ankleshwar Unit Expansion/Upgradation.
- The Company has single segment Pharmaceuticals.
- Information's on standalone Results

PARTICULARS	Quarter ended			Year to date figure for the current period ended	Year to date figure for the Previous period ended	Previous Period ended
	30-09-16	30-06-16	30-09-15	30-09-16	30-09-15	31-03-16
Sr. No.	(Unaudited)	(Unaudited)	(Unaudited)	6 Month (Unaudited)	3 Months (Unaudited)	9 Month (Audited)
1 Total Income from operations (Net)	2,264.53	1,388.19	2,058.69	3,652.72	2,058.69	5,726.96
2 Net Profit/(Loss) from ordinary activities after Tax	62.77	(216.55)	318.63	(153.78)	318.63	482.02
3 Net Profit/(Loss) for the period after Tax (after Extra ordinary items)	62.77	(216.55)	318.63	(153.78)	318.63	482.02

- Figures for previous period have been regrouped/rearranged wherever necessary, to conform to the relevant current period classification.

For LYKA LABS LIMITED

Mumbai
5th November, 2016

N. I. GANDHI (DIN:00021530)
Chairman & Managing Director

on Shetty